Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027

Matinas BioPharma Holdings, Inc.

• Stockholders' equity of $3.02M as of March 31, 2026 fails the $4M minimum under Section 1003(a)(ii) of NYSE American Guide.
• Company also continues to be non-compliant with the $6M equity standard under Section 1003(a)(iii) as previously disclosed.
• NYSE American accepted the Company's plan to regain compliance, granting a plan period through October 2, 2027.
• Common stock will continue trading on NYSE American under symbol MTNB during the plan period; delisting proceedings possible if not compliant by deadline.